MTOR: At the crossroads of aging, chaperones, and Alzheimer's disease

Journal of Neurochemistry

Volumn 124, Issue 6, 2013, Pages 747-748

  Gouras, Gunnar K ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CRYSTALLIN; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHAPERONE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; EDITORIAL; ENZYME INHIBITION; HUMAN; LIFESPAN; LONG TERM POTENTIATION; MEMORY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK FACTOR; SIGNAL TRANSDUCTION; UPREGULATION;

AGED; AGING; ALZHEIMER DISEASE; ANIMALS; HUMANS; MOLECULAR CHAPERONES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84874678359     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12098     Document Type: Editorial

References (10)

1. Caccamo A., Majumder S., Richardson A., Strong R., and, Oddo S., (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 285, 13107-13120.
2. Fonte V., Kipp D. R., Yerg III J., Merin D., Forrestal M., Wagner E., Roberts C. M., and, Link C. D., (2008) Suppression of in vivo beta-amyloid peptide toxicity by overexpression of the HSP-16.2 small chaperone protein. J. Biol. Chem. 283, 784-791.
3. Harrison D. E., Strong R., Sharp Z. D., et al,. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395.
4. Li F., Calingasan N. Y., Yu F., et al,. (2004) Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J. Neurochem. 89, 1308-1312.
5. Lin M. T., and, Beal M. F., (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795.
6. Ma T., Hoeffer C. A., Capetillo-Zarate E., Yu F., Wong H., Lin M. T., Tampellini D., Klann E., Blitzer R. D., and, Gouras G. K., (2010) Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS ONE 5, doi:pii e12845.
7. Pierce A., Podlutskaya N., Halloran J. J., Hussong S. A., Lin P. Y., Burbank R., Strong R., Richardson A., Hart M. J., and, Galvan V., (2012) Overexpression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like deficits in mice modeling the disease. J. Neurochem. Published Online doi: 10.1111/jnc.12080.
8. Spilman P., Podlutskaya N., Hart M. J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., and, Galvan V., (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 5, e9979.
9. Tsokas P., Grace E. A., Chan P., Ma T., Sealfon S. C., Iyengar R., Landau E. M., and, Blitzer R. D., (2005) Local protein synthesis mediates a rapid increase in dendritic elongation factor 1A after induction of late long-term potentiation. J. Neurosci. 25, 5833-5843.
10. Westmark C. J., and, Malter J. S., (2007) FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5, e52.